YG Plus shares reach a seven-month high due to the success of Rosé and Bruno Mars' chart-topping APT.
- YG Plus shares climbed as much as 29.8% on Tuesday
- APT, a track on Spotify's Top 50 Global playlist, also ranked fourth on iTunes' Top 100: Global chart.
The stock price of YG Plus reached a seven-month peak following the global success of the collaboration track between Rosé and Bruno Mars, which was released on October 18th.
On Monday and Tuesday, YG Plus shares experienced a nearly 30% increase in value, following the success of their track "APT" on Spotify's Top 50 Global playlist and its fourth-place ranking on iTunes' Top 100: Global chart.
The game is a South Korean drinking game called "aparteu," which involves playing music and taking turns drinking until the track ends.
The official music video on YouTube has received over 82.9 million views, making it the most-watched male-female duet debut of 2024, surpassing Taylor Swift and Post Malone's Fortnight.
In 2016, Blackpink's member Rosé made her debut under YG Entertainment, which is listed on the Kosdaq stock exchange.
In 2023, she ended her contract with YG Entertainment and signed with The Black Label, a YG subsidiary, as well as U.S. record label Atlantic Records for her solo career.
YG Entertainment subsidiary, YG Plus, distributes records from The Black Label.
YG Entertainment shares climbed as much as 3.53% on Tuesday.
The global music industry's uncertain conditions have caused the parent company's stocks to drop 22.5% year-to-date, despite the boost.
Despite South Korean pop stars breaking records and performing at top music festivals in the West, their management agencies' long-term stock performance has not matched their success.
Business News
You might also like
- SpaceX's Starship is grounded by the FAA after a mid-flight explosion, causing property damage on Turks and Caicos.
- The unparalleled women's basketball league commences on Friday. Discover all the details here.
- PepsiCo faces allegations of price discrimination from the FTC, which claims it is increasing costs for consumers.
- The imposition of tariffs by Trump has prompted China to accelerate the shipment of goods to the US.
- Medicare drug price negotiations include Ozempic in the next round. Here are the 15 medications.